Dr. Birte Wistinghausen is the Clinical Director of the Division of Pediatric Hematology/Oncology, and Assistant Professor of Hematology/Oncology at The Mount Sinai School of Medicine.
Dr. Wistinghausen earned her medical degree at Christian-Albrecht Universitat Kiel in 1993. After a two-year postdoctoral fellowship in the laboratory of Dr. Margaret Karpatkin describing a novel mutation leading to factor IX deficiency she went on to complete an internship and a residency in Pediatrics at New York University Medical Center in New York. She completed her fellowship in pediatric hematology-oncology at New York University Medical Center and Bellevue Hospital and received her first faculty appointment at New York University Medical Center.
As Clinical Director of Pediatric Hematology and Oncology, Dr. Wistinghausen specializes in diagnosing and treating pediatric patients with leukemia, lymphoma, Langerhans cell histiocytosis and pediatric solid tumors as well as treating selected benign hematological problems of childhood such as ITP, hemophagocytic lymphohistiocytosis (HLH) and hematological complications of solid organ transplantation. Dr. Wistinghausen’s research interests focus on clinical and translational research in non-Hodgkin lymphoma and post-transplant lymphoproliferative disease (PTLD). She currently serves as the institutional principal investigator for the Children’s Oncology Group and is a member of the NHL committee of the Children’s Oncology Committee where she has been appointed to spearhead the clinical research for B-lymphoblastic lymphoma in childhood and to develop a new national clinical and translational research protocol for the treatment of post-transplant lymphoproliferative disease with cellular based therapies. Dr. Wistinghausen has published articles about factor XI deficiency, hematological complications of solid organ transplantation, HLH and PTLD.
Pediatric Hematology & Oncology
American Board of Pediatrics
MD, Christian-Albrecht Universitat
Bellevue Hospital Center
Bellevue Hospital Center
First Sydney Q. Cohlan Resident and Fellow Research Award
Department of Pediatrics, New York University Medical Center
ARST0332: Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)
The purpose of this study is to find out if treatment based on each participant’s level of risk will get rid of the tumor and if lessening the treatment for lower risk subjects will decrease the side effects of treatment and still get rid of the tumor.
ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
The overall goal of this study is to compare the effects, good and/or bad, of the chemotherapy drugs carboplatin and isotretinoin on subjects with high risk medulloblastoma and to find out if one or both are better than standard therapy alone. In this study you will get either...
Vincritine, Dactinomycin and Cyclophosphomaide for Rhabdomyosarcoma (Sarcoma)
The purpose of this study is to see if lower doses of cyclophosphamide used together with current standard doses of vincristine and dactinomycin can be as effective or better in curing particpants as the standard doses of vincristine and dactinomycin. Another goal is to see if re...
AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
You are being asked to take part in this research study because you have been diagnosed with T-lymphoblastic leukemia (T-ALL) or T-Lymphoblastic Lymphoma (T-LLy) This study is called a clinical trial. A clinical trial is a research study involving treatment of a disease ...
A Phase III Randomized Trial of Adding Vincristine-topotecan- cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
The purpose of this study is to find if adding the drug combination VTC (vincristine/ topotecan/ cyclophosphamide) to the standard five-drug chemotherapy (cancer fighting medicine) for Ewing sarcoma will get rid of the cancer better than the standard five-drug chemotherapy ...
AREN0534: Treatment for Patients with Bilateral, Multicentric, or Bilaterally- Predisposed Unilateral Wilms Tumor
The goals of this study are:
ACNS0831, Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with\Newly Diagnosed Ependymoma Ages 1 to 21 years
Complete removal of the tumor is the best predictor of survival for patients with ependymoma. Previous experience has shown that when ependymoma is completely removed surgically and then treated with radiation therapy, 67% to 80% of patients are alive 5 years later. Complete remo...
AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
In the United States, nearly 500 children, adolescents and young adults are diagnosed with AML every year and half are cured with standard therapy. In other words, half of the children, adolescents and young adults diagnosed with AML remain with no signs of cancer (remission) for...
ARST0531 - Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC alternating with Vincristine and Irinotecan Hydrochloride in Combination With Radiotherapy for Patients with Intermediate Risk Rhabdomyosarcoma( RMS)
Rhabdomyosarcoma (RMS) is a type of cancer that occurs in the soft tissues of the body like the muscles. The current standard treatment for rhabdomyosarcoma is surgery to remove as much tumor as possible, chemotherapy (anti-cancer drug therapy) with vincristine, dactinomycin a...
ACNS1221 : A Phase II Study For The Treatment Of Non-Metastatic Desmoplastic Medulloblastoma In Children Less Than 4 Years of Age
Several past studies in Europe have shown that infants with Desmoplastic Medulloblastoma had very good treatment outcomes when treated with the usual chemotherapy drugs; (etoposide, cyclophosphamide, cisplatin and vincristine) in addition to the use of a drug called methtrexate g...
Intensified Methotrexate,Nelarabine & Augmented BFM Ther (AALL0434)
The overall goal of this study is to see if we can get rid of the cancer for as long as possible with acceptable side effects of therapy. The purpose of Part I of this study is to collect information on leukemia and the effects of Induction therapy. If patients take part in Part ...
AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is:
ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
You are being asked to take part in this research study because you have a type of cancer called non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). This study is for people with intermediate or high risk NRSTS that cannot be removed by surgery at the time of diagnosis.  ...
Phase III Randomized Study of Chimeric Anti-GC2 in high risk neuroblastoma following myeloablative therapy and autologous stem cell rescue (Protocol - ANBL0032) (Brain)
This is a group-wide phase III Children’s Oncology Group study designed to determine if treatment with monoclonal antibody therapy, plus cytokines and 13-Cis-Retinoic Acid improves that outcome for children with high risk neuroblastoma, when compared to the standard treatment wit...
AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND#73789, NSC# 606869) in the Very High Risk Stratum
In a recently completed COG study, several patients with DS HR-ALL died from infections during treatment, mainly during Induction and Maintenance. Infections and death are known possible complications of treatment, but more of these complications occurred in patients with Down sy...
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
The purpose of this study is: 1) To find out the effectiveness and side effects of the high dose combination chemotherapy treatment for all subjects on this study (A “subject” is a person taking part in the study.) 2) To find out the effectiveness and side effects of higher...
Wistinghausen B, Reischer A, Oddoux C, Ostrer H, Nardi M, Karpatkin M. Severe factor XI deficiency in an Arab family associated with a novel mutation in exon 11. Br J Haematol 1997 Dec; 99(3): 575-7.
Lee CK, Raz R, Gimeno R, Gertner R, Wistinghausen B, Takeshita K, De Pinho RA, Levy DE. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 2002 Jul; 17(1): 63-72.
Ramaswami A, Rosen DJ, Chu J, Wistinghausen B, Arnon R. Fulminant Liver Failure in a Child With β-Thalassemia on Deferasirox: A Case Report. Journal of pediatric hematology/oncology 2016 Jul;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Wistinghausen did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.